Pasatru (garetosmab-grts)
Regeneron Pharmaceuticals (REGN)
ApprovedAug 19, 2026
Marketer take
Joins Sohonos in fibrodysplasia ossificans progressiva and was followed five weeks later by Mirum's Atebrioz, so a very small specialist community will compare three options; Pasatru's label is adults only.
- Sponsor company
- Regeneron Pharmaceuticals (REGN)
- Indication
- To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Therapeutic area
- Rare disease
- Event
- FDA approval
- Date
- Aug 19, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?